Laying of the foundation stone of LFB’s new industrial facility « Usine 2020 », with the French President, Mr. François Hollande
Les Ulis, 7th June 2016 – In attendance of the French President Mr François Hollande, of the President of Hauts-de-France region, Mr Xavier Bertrand, of the President of the Department Council Mr Michel Dagbert, of the President of the Urban Community of Arras, Mr Philippe Rapeneau, the foundation stone of LFB’s « Usine 2020 » was layed on 7th June 2016 on the site of the future plant near Arras (Northern France). This « new generation » plant should allow a three-fold increase in the manufacture of LFB’s plasma derivatives as from 2020. “Usine 2020” represents a 300 million euros investment, and 500 jobs within five years.
« Usine 2020 » : a major industrial project in France in the pharmaceutical sector
LFB’s new industrial facility dedicated to the manufacture of plasma-derived medicinal products is being built in the Actiparc industrial area within the Urban Community of Arras (cities of Bailleul-Sire-Berthoult, Athies and St Laurent Blangy). The facility is to start end of 2020, hence its name « Usine 2020 ».
Built on a 16-hectares field, representing 36 000 qs meters, « Usine 2020 » integrates manufacturing units for immunoglobulins, fibrinogen and albumin, all medicinal products knowing increasing global demand. “Usine 2020” should allow a three-fold increase in the manufacture of LFB’s plasma derivatives in the ten years to come, as well as an optimization of production costs to strengthen the group’s competitiveness in a highly technological field and to meet the highest worldwide standards, and then manufacture for the world.
The whole project corresponds to an investment of around 300 euromillions. It is notably funded by the capital increase of 230 euromillions for LFB SA, wholly subscribed by the French State, currently the unique shareholder of LFB SA. 500 people are expected to work at “Usine 2020” within five years.
« Manufacture in France for the world »
« LFB, a public-owned company doing business in a very competitive sector, needs this new “Usine 2020” to succeed in its international development” outlines Christian Béchon, CEO of the LFB group. “With this high capacity facility, all equipped with cutting-edge technologies, we will manufacture biopharmaceuticals that are needed to meet an increasing demand of health professionals, all around the world. Manufacture in France for the world is our strategy : “Usine 2020” is a key piece of this strategy, and we are besides very pleased to contribute to the economic development of Northern France. We are above all proud and happy to show that a French public company can invest, succeed, create industrial jobs in France.”
Today, the LFB group, a French champion in biological medicinal products, operates four industrial facilities in France, two of them dedicated to plasma derivatives, in les Ulis and Lille. LFB employs 1670 people in France, and invested over 100 euromillions in its industrial capacities in France over the last five years. 272 people have been hired by the company in France since 2011.
About the LFB Group LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products from biological sources for the treatment of serious and often rare diseases in major therapeutic areas, including haemostasis, immunology and intensive care. Number one in France and sixth in the world for plasma-derived medicinal products, the LFB group is also one of the leading European companies in the development and production of proteins and innovative treatment derived from biotechnologies. Relying on its sustained research efforts, the LFB group is implementing a growth strategy to expand its activities to international markets. The LFB group currently markets products in 40 countries throughout the world and achieved a global turnover of 502,4 euromillions in 2015. It employs more than 2,000 people.
Executive Vice-President, Corporate Communications
Phone: +33 (1) 69 82 72 80
email : firstname.lastname@example.org
Phone : +33 (6) 15 51 49 40
email : email@example.com